Literature DB >> 9128947

External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center.

M Wrónski1, M H Maor, B J Davis, R Sawaya, V A Levin.   

Abstract

PURPOSE: Approximately 10% of patients with metastatic renal cell carcinoma are diagnosed with brain metastases. Most of these patients receive palliative radiotherapy and die of progressive brain metastatic disease. This retrospective study examines the M. D. Anderson Cancer Center experience with such patients who received only whole brain radiation therapy (WBRT). METHODS AND MATERIALS: Records of 200 patients with brain metastases from renal carcinoma who were treated at M. D. Anderson Cancer Center between 1976 and 1993 were reviewed. Of these patients, 119 received WBRT only and constitute the basis of this study. Different prognostic factors were analyzed.
RESULTS: Overall median survival time from diagnosis of the brain metastases was 4.4 months. Multiple brain tumors were treated in 70 patients (58.8%) who had a survival of 3.0 months compared with 4.4 months for patients having a single brain metastasis (p = 0.043). Among 117 patients the causes of death were neurologic in 90 (76%), systemic cancer in 19 (16%), and unknown in 9 (8%). Survival rates at 6 months, 1 year, and 2 years, were 33.6, 16.8, and 5.9%, respectively. Patients in whom brain metastases were diagnosed synchronously with a renal primary (n = 24) had a median survival time of 3.4 months compared with 3.2 months for those 95 who were diagnosed metachronously (p < 0.79, NS). In the Cox multivariate analysis of 13 possible prognostic factors, only a single brain metastasis (p = 0.0329), lack of distant metastases at the time of diagnosis (p = 0.0056), and tumor diameter < or = 2 cm (p < 0.0016) were statistically significant.
CONCLUSION: These unsatisfactory results with WBRT suggest that more aggressive approaches, such as surgery or radiosurgery should be applied whenever possible.

Entities:  

Mesh:

Year:  1997        PMID: 9128947     DOI: 10.1016/s0360-3016(97)00006-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  32 in total

Review 1.  Management of brain metastasis: past lessons, modern management, and future considerations.

Authors:  Eugene Koay; Erik P Sulman
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

Review 2.  The ineligible patient: how to treat patients not included in clinical studies.

Authors:  Frances J Mao; Brian I Rini
Journal:  World J Urol       Date:  2013-02-24       Impact factor: 4.226

3.  Surgical resection and postoperative radiosurgery versus staged radiosurgery for large brain metastases.

Authors:  Ammoren E Dohm; Ryan Hughes; William Wheless; Michael Lecompte; Claire Lanier; Jimmy Ruiz; Kounosuke Watabe; Fei Xing; Jing Su; Christina Cramer; Adrian Laxton; Stephen Tatter; Michael D Chan
Journal:  J Neurooncol       Date:  2018-10-26       Impact factor: 4.130

4.  Characterization of the frequency distribution for human hematogenous metastases: evidence for clustering and a power variance function.

Authors:  W S Kendal; F J Lagerwaard; O Agboola
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery.

Authors:  D Clay Cochran; Michael D Chan; Mebea Aklilu; James F Lovato; Natalie K Alphonse; J Daniel Bourland; James J Urbanic; Kevin P McMullen; Edward G Shaw; Stephen B Tatter; Thomas L Ellis
Journal:  J Neurosurg       Date:  2012-03-02       Impact factor: 5.115

6.  Factors that determine local control with gamma knife radiosurgery: The role of primary histology.

Authors:  Paul J Black; Brandi R Page; John T Lucas; Ryan T Hughes; Adrian W Laxton; Stephen B Tatter; Michael T Munley; Michael D Chan
Journal:  J Radiosurg SBRT       Date:  2015

7.  Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.

Authors:  Jonathan Verma; Eric Jonasch; Pamela Allen; Nizar Tannir; Anita Mahajan
Journal:  Cancer       Date:  2011-04-11       Impact factor: 6.860

8.  Do we have a "game changer" in treating patients with brain metastasis from renal cell carcinoma?

Authors:  Olga Vornicova; Gil Bar-Sela
Journal:  Ann Transl Med       Date:  2019-12

9.  Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy.

Authors:  Emory R McTyre; Adam G Johnson; Jimmy Ruiz; Scott Isom; John T Lucas; William H Hinson; Kounosuke Watabe; Adrian W Laxton; Stephen B Tatter; Michael D Chan
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

10.  Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis.

Authors:  Thekla Meyners; Christine Heisterkamp; Jan-Dirk Kueter; Theo Veninga; Lukas J A Stalpers; Steven E Schild; Dirk Rades
Journal:  BMC Cancer       Date:  2010-10-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.